


# Psychopharmacology

Drugs, the Brain, and Behavior

THIRD EDITION



Jerrold S. Meyer ■ Linda F. Quenzer

# Psychopharmacology

Drugs, the Brain, and Behavior


THIRD EDITION



# Psychopharmacology

Drugs, the Brain, and Behavior

THIRD EDITION



**Jerrold S. Meyer**

*University of Massachusetts*

**Linda F. Quenzer**

*University of Hartford*


**Chapter 20, Neurodegenerative Diseases**

*By Jennifer R. Yates, University of Alabama*



SINAUER ASSOCIATES

NEW YORK OXFORD  
OXFORD UNIVERSITY PRESS



## About the cover

“Mind on Fire,” portrait of the artist’s brain based on sagittal MRI. By Elizabeth Jameson. ([www.jamesonfineart.com](http://www.jamesonfineart.com))

## Psychopharmacology Drugs, the Brain, and Behavior, Third Edition

Oxford University Press is a department of the University of Oxford. It furthers the University’s objective of excellence in research, scholarship, and education by publishing worldwide. Oxford is a registered trade mark of Oxford University Press in the UK and certain other countries.

Published in the United States of America by Oxford University Press  
198 Madison Avenue, New York, NY 10016, United States of America

© 2019 Oxford University Press  
Sinuer Associates is an imprint of Oxford University Press.

For titles covered by Section 112 of the US Higher Education Opportunity Act, please visit [www.oup.com/us/he](http://www.oup.com/us/he) for the latest information about pricing and alternate formats.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing of Oxford University Press, or as expressly permitted by law, by license, or under terms agreed with the appropriate reproduction rights organization. Inquiries concerning reproduction outside the scope of the above should be sent to the Rights Department, Oxford University Press, at the address above.

You must not circulate this work in any other form and you must impose this same condition on any acquirer.

Address editorial correspondence to:  
Sinuer Associates  
23 Plumtree Road  
Sunderland, MA 01375 U.S.A.  
[publish@sinuer.com](mailto:publish@sinuer.com)

Address orders, sales, license, permissions, and translation inquiries to:  
Oxford University Press U.S.A.  
2001 Evans Road  
Cary, NC 27513 U.S.A.  
Orders: 1-800-445-9714

### Library of Congress Cataloging-in-Publication Data

Names: Meyer, Jerrold S., 1947- author.  
Title: Psychopharmacology : drugs, the brain, and behavior / Jerrold S. Meyer, Linda F. Quenzer.  
Description: Third edition. | Sunderland, Massachusetts, USA : Oxford University Press, [2019] | Includes bibliographical references and index.  
Identifiers: LCCN 2017049700 | ISBN 9781605355559  
Subjects: LCSH: Psychotropic drugs--Pharmacokinetics. | Psychotropic drugs--Therapeutic use.  
Classification: LCC RM315 .M478 2019 | DDC 615.7/88--dc23  
LC record available at <https://lccn.loc.gov/2017049700>

The *Diagnostic and Statistical Manual of Mental Disorders, DSM, DSM-IV, DSM-IV-TR, and DSM-5* are registered trademarks of the American Psychiatric Association. Oxford University Press is not associated with the American Psychiatric Association or with any of its products or publications, nor do the views expressed herein represent the policies and opinions of the American Psychiatric Association.

9 8 7 6 5 4 3 2 1

Printed in the United States of America

*To our students, who challenge and inspire us,  
and to the many outstanding researchers  
whose work is central to this book's contents.*

# Brief Contents

<b>CHAPTER 1</b>	Principles of Pharmacology	3
<b>CHAPTER 2</b>	Structure and Function of the Nervous System	45
<b>CHAPTER 3</b>	Chemical Signaling by Neurotransmitters and Hormones	83
<b>CHAPTER 4</b>	Methods of Research in Psychopharmacology	117
<b>CHAPTER 5</b>	Catecholamines	159
<b>CHAPTER 6</b>	Serotonin	189
<b>CHAPTER 7</b>	Acetylcholine	213
<b>CHAPTER 8</b>	Glutamate and GABA	231
<b>CHAPTER 9</b>	Drug Abuse and Addiction	265
<b>CHAPTER 10</b>	Alcohol	307
<b>CHAPTER 11</b>	The Opioids	351
<b>CHAPTER 12</b>	Psychomotor Stimulants: Cocaine, Amphetamine, and Related Drugs	391
<b>CHAPTER 13</b>	Nicotine and Caffeine	429
<b>CHAPTER 14</b>	Marijuana and the Cannabinoids	467
<b>CHAPTER 15</b>	Hallucinogens, PCP, and Ketamine	501
<b>CHAPTER 16</b>	Inhalants, GHB, and Anabolic–Androgenic Steroids	527
<b>CHAPTER 17</b>	Disorders of Anxiety and Impulsivity and the Drugs Used to Treat These Disorders	559
<b>CHAPTER 18</b>	Affective Disorders: Antidepressants and Mood Stabilizers	601
<b>CHAPTER 19</b>	Schizophrenia: Antipsychotic Drugs	633
<b>CHAPTER 20</b>	Neurodegenerative Diseases	671

# Contents

Preface xvii

## 1

### Principles of Pharmacology 3

#### Pharmacology: The Science of Drug Action 4

Placebo effect 5

**Box 1.1 Pharmacology in Action** Naming Drugs 6

#### Pharmacokinetic Factors Determining Drug Action 7

Methods of drug administration influence the onset of drug action 8

Multiple factors modify drug absorption 12

Drug distribution is limited by selective barriers 15

Depot binding alters the magnitude and duration of drug action 18

Biotransformation and elimination of drugs contribute to bioavailability 19

#### Therapeutic Drug Monitoring 25

**Box 1.2 Pharmacology in Action** Interspecies Drug Dose Extrapolation 25

#### Pharmacodynamics: Drug–Receptor Interactions 27

**Box 1.3 Pharmacology in Action** Drug Categories 28

Extracellular and intracellular receptors have several common features 30

Dose–response curves describe receptor activity 31

The therapeutic index calculates drug safety 32

Receptor antagonists compete with agonists for binding sites 33

#### Biobehavioral Effects of Chronic Drug Use 34

Repeated drug exposure can cause tolerance 35

Chronic drug use can cause sensitization 38

#### Pharmacogenetics and Personalized Medicine in Psychiatry 39

## 2

### Structure and Function of the Nervous System 45

#### Cells of the Nervous System 46

Neurons have three major external features 46

**Box 2.1 The Cutting Edge** Embryonic Stem Cells 47

Characteristics of the cell membrane are critical for neuron function 54

Glial cells provide vital support for neurons 55

**Box 2.2 Of Special Interest** Astrocytes 56

#### Electrical Transmission within a Neuron 58

Ion distribution is responsible for the cell's resting potential 58

Local potentials are small, transient changes in membrane potential 60

Sufficient depolarization at the axon hillock opens voltage-gated Na<sup>+</sup> channels, producing an action potential 61

Drugs and poisons alter axon conduction 63

#### Organization of the Nervous System 65

**Box 2.3 The Cutting Edge** Finding Your Way in the Nervous System 65

The nervous system comprises the central and peripheral divisions 66

CNS functioning is dependent on structural features 68



The CNS has six distinct regions reflecting embryological development 70

**Box 2.4 Of Special Interest** Neuroendocrine Response to Stress 76

The cerebral cortex is divided into four lobes, each having primary, secondary, and tertiary areas 76

Rat and human brains have many similarities and some differences 79

## 3

### Chemical Signaling by Neurotransmitters and Hormones 83

#### Chemical Signaling between Nerve Cells 84

##### Neurotransmitter Synthesis, Release, and Inactivation 86

Neurotransmitters encompass several different kinds of chemical substances 86

**Box 3.1 Clinical Applications** Orexin-Based Medications: New Approaches to the Treatment of Sleep Disorders 87

Neuropeptides are synthesized by a different mechanism than other transmitters 90

Neuromodulators are chemicals that don't act like typical neurotransmitters 91

Classical transmitter release involves exocytosis and recycling of synaptic vesicles 91

Lipid and gaseous transmitters are not released from synaptic vesicles 95

Several mechanisms control the rate of neurotransmitter release by nerve cells 96

Neurotransmitters are inactivated by reuptake and by enzymatic breakdown 97

#### Neurotransmitter Receptors and Second-Messenger Systems 98

There are two major families of neurotransmitter receptors 99

Second messengers work by activating specific protein kinases within a cell 102

Tyrosine kinase receptors mediate the effects of neurotrophic factors 104

#### Pharmacology of Synaptic Transmission 104

##### Synaptic Plasticity 105

##### The Endocrine System 107

Endocrine glands can secrete multiple hormones 107

Mechanisms of hormone action vary 109

Why is the endocrine system important to pharmacologists? 111

**Box 3.2 Pharmacology in Action** Sex Hormones and Drug Abuse 112

## 4

### Methods of Research in Psychopharmacology 117

#### Research Methods for Evaluating the Brain and Behavior 118

##### Techniques in Behavioral Pharmacology 118

##### Evaluating Animal Behavior 118

Animal testing needs to be valid and reliable to produce useful information 118

A wide variety of behaviors are evaluated by psychopharmacologists 120

**Box 4.1 Pharmacology in Action** Using the Three-Chamber Social Interaction Test 125

**Box 4.2 Clinical Applications** Drug Testing for FDA Approval 131

##### Techniques in Neuropharmacology 134

#### Multiple Neurobiological Techniques for Assessing the CNS 134

Stereotaxic surgery is needed for accurate in vivo measures of brain function 134

Neurotransmitters, receptors, and other proteins can be quantified and visually located in the CNS 138

New tools are used for imaging the structure and function of the brain 145

Genetic engineering helps neuroscientists to ask and answer new questions 150

**Box 4.3 Pharmacology in Action** Transgenic Model of Huntington's Disease 153

Behavioral and neuropharmacological methods complement one another 155

## 5

## Catecholamines 159

**Catecholamine Synthesis, Release, and Inactivation 160**

Tyrosine hydroxylase catalyzes the rate-limiting step in catecholamine synthesis 160

Catecholamines are stored in and released from synaptic vesicles 161

Catecholamine inactivation occurs through the combination of reuptake and metabolism 164

**Organization and Function of the Dopaminergic System 166**

Two important dopaminergic cell groups are found in the midbrain 166

Ascending dopamine pathways have been implicated in several important behavioral functions 167

**Box 5.1 Clinical Applications** Mutations That Affect Dopamine Neurotransmission 168

There are five main subtypes of dopamine receptors organized into D<sub>1</sub>- and D<sub>2</sub>-like families 171

Dopamine receptor agonists and antagonists affect locomotor activity and other behavioral functions 172

**Box 5.2 The Cutting Edge** Using Molecular Genetics to Study the Dopaminergic System 174

**Organization and Function of the Noradrenergic System 177**

Norepinephrine is an important transmitter in both the central and peripheral nervous systems 177

Norepinephrine and epinephrine act through  $\alpha$ - and  $\beta$ -adrenergic receptors 178

The central noradrenergic system plays a significant role in arousal, cognition, and the consolidation of emotional memories 179

Several medications work by stimulating or inhibiting peripheral adrenergic receptors 183

## 6

## Serotonin 189

**Serotonin Synthesis, Release, and Inactivation 190**

Serotonin synthesis is regulated by enzymatic activity and precursor availability 190

Similar processes regulate storage, release, and inactivation of serotonin and the catecholamines 192

**Box 6.1 History of Psychopharmacology** “Ecstasy”—Harmless Feel-Good Drug, Dangerous Neurotoxin, or Miracle Medication? 193

**Organization and Function of the Serotonergic System 196**

The serotonergic system originates in the brainstem and projects to all forebrain areas 196

The firing of dorsal raphe serotonergic neurons varies with behavioral state and in response to rewards and punishments 197

There is a large family of serotonin receptors, most of which are metabotropic 198

Multiple approaches have identified several behavioral and physiological functions of serotonin 200

**Box 6.2 The Cutting Edge** Serotonin and Aggression 203

## 7

## Acetylcholine 213

**Acetylcholine Synthesis, Release, and Inactivation 214**

Acetylcholine synthesis is catalyzed by the enzyme choline acetyltransferase 214

Many different drugs and toxins can alter acetylcholine storage and release 214

Acetylcholinesterase is responsible for acetylcholine breakdown 215

**Box 7.1 Pharmacology In Action** Botulinum Toxin—Deadly Poison, Therapeutic Remedy, and Cosmetic Aid 216

**Organization and Function of the Cholinergic System 219**

Cholinergic neurons play a key role in the functioning of both the peripheral and central nervous systems 219

**Box 7.2 The Cutting Edge** Acetylcholine and Cognitive Function 220

There are two acetylcholine receptor subtypes: nicotinic and muscarinic 222

## 8

## Glutamate and GABA 231

## Glutamate 232

**Glutamate Synthesis, Release, and Inactivation 232**

Neurons generate glutamate from the precursor glutamine 232

Glutamate packaging into vesicles and uptake after release are mediated by multiple transport systems 232

**Organization and Function of the Glutamatergic System 235**

Glutamate is the neurotransmitter used in many excitatory pathways in the brain 235

Both ionotropic and metabotropic receptors mediate the synaptic effects of glutamate 236

**Box 8.1 Clinical Applications** Fragile X Syndrome and Metabotropic Glutamate Receptor Antagonists: A Contemporary Saga of Translational Medicine 239

AMPA and NMDA receptors play a key role in learning and memory 239

High levels of glutamate can be toxic to nerve cells 245

## GABA 251

**GABA Synthesis, Release, and Inactivation 251**

GABA is synthesized by the enzyme glutamic acid decarboxylase 251

GABA packaging into vesicles and uptake after release are mediated by specific transporter proteins 251

GABA is coreleased with several other classical neurotransmitters 253

**Organization and Function of the GABAergic System 254**

Some GABAergic neurons are interneurons, while others are projection neurons 254

The actions of GABA are primarily mediated by ionotropic GABA<sub>A</sub> receptors 254

**Box 8.2 Clinical Applications** GABA and Epilepsy 255

GABA also signals using metabotropic GABA<sub>B</sub> receptors 260

## 9

## Drug Abuse and Addiction 265

**Introduction to Drug Abuse and Addiction 266**

Drugs of abuse are widely consumed in our society 266

Drug use in our society has increased and has become more heavily regulated over time 267

**Features of Drug Abuse and Addiction 270**

Drug addiction is considered to be a chronic, relapsing behavioral disorder 270

There are two types of progression in drug use 272

**Box 9.1 Of Special Interest** Should the Term *Addiction* Be Applied to Compulsive Behavioral Disorders That Don't Involve Substance Use? 273

Which drugs are the most addictive? 275

**Factors That Influence the Development and Maintenance of Drug Abuse and Addiction 276**

The addiction potential of a substance is influenced by its route of administration 277

Most abused drugs exert rewarding and reinforcing effects 277

Drug dependence leads to withdrawal symptoms when abstinence is attempted 280

Discriminative stimulus effects contribute to drug-seeking behavior 282

Genetic factors contribute to the risk for addiction 283

Psychosocial variables also contribute to addiction risk 285

The factors contributing to drug addiction can be combined into a biopsychosocial model 287

**The Neurobiology of Drug Addiction 289**

Drug reward and incentive salience drive the binge-intoxication stage of drug use 289

The withdrawal/negative affect stage is characterized by stress and by the recruitment of an antireward circuit 292

The preoccupation/anticipation stage involves dysregulation of prefrontal cortical function and corticostriatal circuitry 294

Molecular neuroadaptations play a key role in the transition to an addicted state 296

Is addiction a disease? 299

## 10 Alcohol 307

### Psychopharmacology of Alcohol 308

- Alcohol has a long history of use 308
- What is an alcohol and where does it come from? 309
- The pharmacokinetics of alcohol determines its bioavailability 310
- Chronic alcohol use leads to both tolerance and physical dependence 313
- Alcohol affects many organ systems 315
- Box 10.1 Pharmacology in Action** The Role of Expectation in Alcohol-Enhanced Human Sexual Response 315

### Neurochemical Effects of Alcohol 325

- Animal models are vital for alcohol research 325
- Alcohol acts on multiple neurotransmitters 327

### Alcohol Use Disorder (AUD) 335

- Defining alcohol use disorder and estimating its incidence have proved difficult 335
- The causes of alcohol use disorder are multimodal 338
- Multiple treatment options provide hope for rehabilitation 342

## 11 The Opioids 351

### Narcotic Analgesics 352

- The opium poppy has a long history of use 352
- Minor differences in molecular structure determine behavioral effects 353
- Bioavailability predicts both physiological and behavioral effects 354
- Opioids have their most important effects on the CNS and on the gastrointestinal tract 354
- Box 11.1 Clinical Applications** Saving a Life: Naloxone for Opioid Overdoses 355

### Opioid Receptors and Endogenous Neuropeptides 357

- Receptor binding studies identified and localized opioid receptors 357
- Four opioid receptor subtypes exist 358
- Several families of naturally occurring opioid peptides bind to these receptors 360
- Box 11.2 The Cutting Edge** Science in Action 361
- Opioid receptor-mediated cellular changes are inhibitory 365

### Opioids and Pain 366

- The two components of pain have distinct features 367
- Opioids inhibit pain transmission at spinal and supraspinal levels 369
- Other forms of pain control depend on opioids 371

### Opioid Reinforcement, Tolerance, and Dependence 374

- Animal testing shows significant reinforcing properties 376
- Dopaminergic and nondopaminergic components contribute to opioid reinforcement 376
- Long-term opioid use produces tolerance, sensitization, and dependence 377

### Box 11.3 Of Special Interest

- The Opioid Epidemic 379
- Several brain areas contribute to the opioid abstinence syndrome 381
- Neurobiological adaptation and rebound constitute tolerance and withdrawal 381
- Environmental cues have a role in tolerance, drug abuse, and relapse 382

### Treatment Programs for Opioid Use Disorder 383

- Detoxification is the first step in the therapeutic process 383
- Treatment goals and programs rely on pharmacological support and counseling 384

## 12

## Psychomotor Stimulants: Cocaine, Amphetamine, and Related Drugs 391

**Cocaine 392****Background and History 392****Basic Pharmacology of Cocaine 393****Mechanisms of Cocaine Action 395****Acute Behavioral and Physiological Effects of Cocaine 397**

Cocaine stimulates mood and behavior 398

Cocaine's physiological effects are mediated by the sympathetic nervous system 399

Dopamine is important for many effects of cocaine and other psychostimulants 399

Brain imaging has revealed the neural mechanisms of psychostimulant action in humans 401

Several DA receptor subtypes mediate the functional effects of psychostimulants 402

**Cocaine Abuse and the Effects of Chronic Cocaine Exposure 403**

Experimental cocaine use may escalate over time to a pattern of cocaine abuse and dependence 403

Chronic cocaine exposure leads to significant behavioral and neurobiological changes 405

**Box 12.1 The Cutting Edge** Neurochemical Mechanisms of Cocaine Tolerance and Sensitization 406

Repeated or high-dose cocaine use can produce serious health consequences 409

Pharmacological, behavioral, and psychosocial methods are used to treat cocaine abuse and dependence 409

**The Amphetamines 412****Background and History 412****Basic Pharmacology of the Amphetamines 413****Mechanisms of Amphetamine and Methamphetamine Action 414****Behavioral and Neural Effects of Amphetamines 415**

Amphetamine and methamphetamine have therapeutic uses 415

High doses or chronic use of amphetamines can cause a variety of adverse effects 415

**Methylphenidate, Modafinil, and Synthetic Cathinones 418****Methylphenidate 418**

**Box 12.2 Clinical Applications** Psychostimulants and ADHD 420

**Modafinil 422****Synthetic Cathinones 423**

## 13

## Nicotine and Caffeine 429

**Nicotine 430****Background and History 430****Basic Pharmacology of Nicotine and Its Relationship to Smoking 431**

Features of tobacco smoking and nicotine pharmacokinetics 431

Features of e-cigarette vaping and nicotine pharmacokinetics 431

Nicotine metabolism 432

**Mechanisms of Action 432****Behavioral and Physiological Effects 433**

Nicotine elicits different mood changes in smokers compared with nonsmokers 434

Nicotine enhances cognitive function 434

Nicotine exerts both reinforcing and aversive effects 436

Nicotine produces a wide range of physiological effects 438

Nicotine is a toxic substance that can be fatal at high doses 439

Chronic exposure to nicotine induces tolerance and dependence 440

**Cigarette Smoking and Vaping 443**

What percentage of the population are current users of tobacco and/or e-cigarettes? 443

Nicotine users progress through a series of stages in their pattern and frequency of use 444

**Box 13.1 The Cutting Edge** How Safe Are E-cigarettes? 446

Why do smokers smoke and vapers vape? 447

Smoking is a major health hazard and a cause of premature death 450

Behavioral and pharmacological strategies are used to treat tobacco dependence 451

## Caffeine 455

### Background 455

### Basic Pharmacology of Caffeine 456

### Behavioral and Physiological Effects 456

Acute subjective and behavioral effects of caffeine depend on dose and prior exposure 456

Caffeine consumption can enhance sports performance 457

Regular caffeine use leads to tolerance and dependence 458

Caffeine and caffeine-containing beverages pose health risks but also exert therapeutic benefits 459

### Mechanisms of Action 460

## 14 Marijuana and the Cannabinoids 467

### Background and History of Cannabis and Marijuana 468

Forms of cannabis and their chemical constituents 468

History of cannabis 468

### Basic Pharmacology of Marijuana 470

THC 470

Cannabidiol 471

### Mechanisms of Action 472

Cannabinoid effects are mediated by cannabinoid receptors 472

Pharmacological and genetic studies reveal the functional roles of cannabinoid receptors 473

Endocannabinoids are cannabinoid receptor agonists synthesized by the body 474

### Acute Behavioral and Physiological Effects of Cannabinoids 480

Cannabis consumption produces a dose-dependent state of intoxication 480

Marijuana use can lead to deficits in memory and other cognitive processes 481

Rewarding and reinforcing effects of cannabinoids have been studied in both humans and animals 482

### Cannabis Abuse and the Effects of Chronic Cannabis Exposure 484

Chronic use of cannabis can lead to the development of a cannabis use disorder 485

Chronic cannabis use can lead to adverse behavioral, neurobiological, and health effects 489

**Box 14.1 Of Special Interest** Beyond Cannabis: The Rise of Synthetic Cannabinoids 495

## 15 Hallucinogens, PCP, and Ketamine 501

### Hallucinogenic Drugs 502

#### Mescaline 502

#### Psilocybin 502

#### Dimethyltryptamine and Related Tryptamines 504

#### LSD 504

**Box 15.1 History of Pharmacology**  
The Discovery of LSD 505

#### NBOMes 506

#### Salvinorin A 507

### Pharmacology of Hallucinogenic Drugs 507

Different hallucinogenic drugs vary in potency and in their time course of action 507

Hallucinogens produce a complex set of psychological and physiological responses 508

Most hallucinogenic drugs share a common indoleamine or phenethylamine structure 509

Indoleamine and phenethylamine hallucinogens are 5-HT<sub>2A</sub> receptor agonists 510

Salvinorin A is a κ-opioid receptor agonist 511

The neural mechanisms underlying hallucinogenesis are not yet fully understood 511

Hallucinogenic drug use leads to adverse effects in some users 511

Can hallucinogenic drugs be used therapeutically? 513

## PCP and Ketamine 515

### Background and History 515

### Pharmacology of PCP and Ketamine 516

PCP and ketamine produce a state of dissociation 516

PCP and ketamine are noncompetitive antagonists of NMDA receptors 517

PCP and ketamine have significant abuse potential 517

Use of PCP, ketamine, or related drugs can cause a variety of adverse consequences 519

**Box 15.2 Pharmacology In Action** Getting High on Cough Syrup 520

Novel therapeutic applications have been proposed for ketamine 522

# 16

## Inhalants, GHB, and Anabolic–Androgenic Steroids 527

### Inhalants 528

#### Background 528

Inhalants comprise a range of substances including volatile solvents, fuels, halogenated hydrocarbons, anesthetics, and nitrites 528

Abused inhalants are rapidly absorbed and readily enter the brain 528

These substances are particularly favored by children and adolescents 529

#### Behavioral and Neural Effects 530

Many inhalant effects are similar to alcohol intoxication 530

Chronic inhalant use can lead to tolerance and dependence 530

Rewarding and reinforcing effects have been demonstrated in animals 530

Inhalants have complex effects on central nervous system (CNS) function and behavioral activity 531

Health risks have been associated with inhalant abuse 532

### Gamma-Hydroxybutyrate 534

#### Background 534

#### Behavioral and Neural Effects 535

GHB produces behavioral sedation, intoxication, and learning deficits 535

GHB and its precursors have reinforcing properties 535

Effects of GHB are mediated by multiple mechanisms 536

### Medical and Recreational Uses of GHB 538

GHB is used therapeutically for the treatment of narcolepsy and alcoholism 538

GHB has significant abuse potential when used recreationally 539

### Anabolic–Androgenic Steroids 540

#### Background and History 541

Anabolic–androgenic steroids are structurally related to testosterone 541

Anabolic–androgenic steroids were developed to help build muscle mass and enhance athletic performance 542

Anabolic–androgenic steroids are currently taken by many adolescent and adult men 543

Anabolic–androgenic steroids are taken in specific patterns and combinations 543

#### Pharmacology of Anabolic–Androgenic Steroids 545

Research is beginning to unravel the mechanism of action of anabolic–androgenic steroids on muscle 545

Many adverse side effects are associated with anabolic–androgenic steroid use 546

Regular anabolic–androgenic steroid use causes dependence in some individuals 548

**Box 16.1 Of Special Interest** Anabolic–Androgenic Steroids and “Roid Rage” 549

Testosterone has an important role in treating hypogonadism 552

## 17

## Disorders of Anxiety and Impulsivity and the Drugs Used to Treat These Disorders 559

**Neurobiology of Anxiety 560**

What is anxiety? 560

The amygdala is important to emotion-processing circuits 561

Multiple neurotransmitters mediate anxiety 564

**Box 17.1 The Cutting Edge** Neural Mechanism Responsible for High Tonic Cell Firing Mediating Anxiety 566

Genes and environment interact to determine the tendency to express anxiety 574

The effects of early stress are dependent on timing 576

The effects of early stress vary with gender 577

**Characteristics of Anxiety Disorders 579****Drugs for Treating Anxiety, OCD, and PTSD 587**

Barbiturates are the oldest sedative-hypnotics 588

Benzodiazepines are highly effective for anxiety reduction 590

Second-generation anxiolytics produce distinctive clinical effects 595

Antidepressants relieve anxiety and depression 596

Many novel approaches to treating anxiety are being developed 597

## 18

## Affective Disorders: Antidepressants and Mood Stabilizers 601

**Characteristics of Affective Disorders 602**

Major depression damages the quality of life 602

In bipolar disorder moods alternate from mania to depression 602

Risk factors for mood disorders are biological and environmental 604

**Animal Models of Affective Disorders 608**

Models of bipolar disorder 608

**Neurochemical Basis of Mood Disorders 610**

Serotonin dysfunction contributes to mood disorders 611

Norepinephrine activity is altered by antidepressants 614

Norepinephrine and serotonin modulate one another 615

**Neurobiological Models of Depression 615**

**Box 18.1 The Cutting Edge** Epigenetic Modifications in Psychopathology and Treatment 618

**Therapies for Affective Disorders 621**

Monoamine oxidase inhibitors are the oldest antidepressant drugs 621

Tricyclic antidepressants block the reuptake of norepinephrine and serotonin 623

Second-generation antidepressants have different side effects 624

Third-generation antidepressants have distinctive mechanisms of action 625

Drugs for treating bipolar disorder stabilize the highs and the lows 628

## 19

## Schizophrenia: Antipsychotic Drugs 633

**Characteristics of Schizophrenia 634**

There is no defining cluster of schizophrenic symptoms 634

**Etiology of Schizophrenia 636**

Abnormalities of brain structure and function occur in individuals with schizophrenia 636

Genetic, environmental, and developmental factors interact 639

**Box 19.1 The Cutting Edge** Epigenetic Modifications and Risk for Schizophrenia 642

**Preclinical Models of Schizophrenia 646**

**Box 19.2 Pharmacology In Action**

The Prenatal Inflammation Model of Schizophrenia 648

**Neurochemical Models of Schizophrenia 650**

Abnormal dopamine function contributes to schizophrenic symptoms 650



The neurodevelopmental model integrates anatomical and neurochemical evidence 651

Glutamate and other neurotransmitters contribute to symptoms 652

### Classic Neuroleptics and Atypical Antipsychotics 650

Phenothiazines and butyrophenones are classic neuroleptics 654

Dopamine receptor antagonism is responsible for antipsychotic action 655

Side effects are directly related to neurochemical action 657

Atypical antipsychotics are distinctive in several ways 660

Practical clinical trials help clinicians make decisions about drugs 663

There are renewed efforts to treat the cognitive symptoms 664

## 20 Neurodegenerative Diseases 671

### Parkinson's Disease and Alzheimer's Disease 672

#### Parkinson's Disease 672

The clinical features of PD are primarily motor related 672

Patients with Parkinson's may also develop dementia 673

The primary pathology of PD is a loss of dopaminergic neurons in the substantia nigra 673

Animal models of PD have strengths and limitations 676

Pharmacological treatments for PD are primarily symptomatic, not disease altering 676

There are several unmet needs in PD diagnosis and treatment 677

#### Alzheimer's Disease 678

AD is defined by several pathological cellular disturbances 679

There are several behavioral, health, and genetic risk factors for AD 681

Alzheimer's disease cannot be definitively diagnosed until postmortem analysis 682

Several different animal models contribute to our understanding of AD 683

Symptomatic treatments are available, and several others are under study for slowing disease progression 683

**Box 20.1 The Cutting Edge** Alzheimer's Disease: It's all in your gut??? 684

### Other Major Neurodegenerative Diseases 685

#### Huntington's Disease 685

Symptoms 686

Only symptomatic treatments are available for HD; none alter disease progression 686

#### Amyotrophic Lateral Sclerosis 687

The symptoms and disease progression in ALS are devastating 687

The loss of motor neurons in ALS is complicated and poorly understood 687

Two medications exist that are approved for ALS treatment 688

#### Multiple Sclerosis 688

The symptoms of MS are variable and unpredictable 689

Diagnosis 689

Causes of MS 690

Treatments fall into several categories for MS and can be very effective 691

**Box 20.2 Pharmacology in Action** Can We Repair or Replace Myelin? 693

Glossary G-1

References R-1

Author Index AI-1

Subject Index SI-1

# Preface

When we wrote the preface to the Second Edition of *Psychopharmacology: Drugs, the Brain, and Behavior*, we were struck by the many exciting developments in the field and the remarkable rate of progress elucidating the underlying neurobiological mechanisms of psychoactive drug action. This has not changed over the 5 years since the publication of that edition. The entire field of neuroscience, including neuropsychopharmacology, continues to be driven by technical advances. Using optogenetics, neurobiologists can activate or suppress anatomically and molecularly defined populations of nerve cells with amazing temporal precision. Neuropharmacologists can visualize the 3-dimensional structure of neurotransmitter receptors, enabling synthetic chemists to design novel agonist or antagonist drugs with much greater selectivity than could have been possible before. And huge projects like the Human Connectome Project ([www.humanconnectomeproject.org](http://www.humanconnectomeproject.org)) are using the most advanced neuroimaging techniques to map the detailed circuitry of the living human brain. Because of these technical innovations, we continue to add new information to Chapter 4, on *Methods of Research in Psychopharmacology*. Readers may choose to go through the chapter in its entirety to familiarize themselves with all of the neuropharmacological and behavioral methods reviewed, or they may choose to use the chapter as a reference source when they encounter an unfamiliar method in one of the book's later chapters.

Development and introduction of new pharmaceutical compounds continues as well, although the emphasis has somewhat shifted away from the large pharmaceutical companies to a greater reliance on drug discovery efforts by researchers at universities and medical centers. Statistics show that development of new drugs for CNS disorders (e.g., schizophrenia, depression, and Alzheimer's disease) costs more than for other kinds of disorders, and the failure rate is significantly higher. These data have caused many of the large companies to downsize their CNS drug discovery programs. As you read the chapters on drug addiction, mental disorders, and neurodegenerative disorders, it

will become apparent that new medications for these disorders are being introduced at a slower rate than expected, despite ongoing research that continues to identify potential new molecular targets for pharmacotherapy. For this reason, we must admit that exciting advances in understanding the basic structure and function of the nervous system have not yet led to similar progress in treating, much less "curing," disorders of this system. We came to the same conclusion when writing the preface to the Second Edition, so it's disappointing that the hoped-for surge in medication development failed to occur during the intervening period.

As before, this new edition of the text is completely updated to incorporate the latest research findings, methodological advances, and novel drugs of abuse. Regarding the latter, illicit drug labs in the United States and abroad are working hard to turn out massive amounts of recreational drugs, whether already known compounds such as cocaine or fentanyl, or novel synthetic compounds that can only be identified by submitting drug seizures to advanced forensic laboratories for chemical analysis. The national drug epidemic involving fentanyl, heroin, and other opioid compounds is discussed in Chapter 11. New and, in some cases, highly dangerous stimulant and cannabinoid drugs are introduced in Chapters 12, 14, and 15 respectively. Most chapters have new opening vignettes and breakout boxes, and new photographs, drawings, and graphs have been added to bring attention both to updated material and to completely new topic areas for discussion.

Importantly, in preparing this next edition of the book we have maintained our conviction that a deep understanding of the relationship between drugs and behavior requires basic knowledge of how the nervous system works and how different types of drugs interact with nervous system function (i.e., mechanisms of drug action). We have also continued to present the methods and findings from behavioral pharmacological studies using animal models alongside key studies from the human clinical research literature. Pharmacologists must depend on *in vitro* preparations and laboratory

animal studies for determining mechanisms of drug action, for screening new compounds for potential therapeutic activity, and, of course, for basic toxicology and safety testing. In cases in which clinical trials have already been performed based on promising preclinical results, both sets of findings are presented. In other instances in which clinical trials had not yet been undertaken at the time of our writing, we have striven to point you toward new directions of drug development so that you can seek out the latest information using your own research efforts.

A new point of emphasis in the text concerns neural circuits as mediators of behavior and as targets of drug action. As implied above in referring to the Human Connectome Project, focusing on circuits instead of cells as the nervous system's functional units is the contemporary way to think about how our brains control our actions, and how drugs, whether recreational or medicinal, alter our subjective awareness and behavior.

The Third Edition of *Psychopharmacology: Drugs, the Brain, and Behavior* retains the same four-section organization as the previous editions. Chapters 1 through 4 provide extensive foundation materials, including the basic principles of pharmacology, neurophysiology and neuroanatomy, cell signaling (primarily synaptic transmission), and current methods in behavioral assessment and neuropharmacology. An increased use of clinical examples demonstrates the relevance of the material to real-life issues. Chapters 5 through 8 describe key features of major neurotransmitter systems, including the catecholamines, serotonin, acetylcholine, glutamate, and GABA. These are the neurotransmitter

systems most often associated with psychoactive drug effects, and presentation of their neurochemistry, anatomy, and function lays the groundwork for the chapters that follow. Chapters 9 through 16 cover theories and mechanisms of drug addiction and all the major substances of abuse. Finally, Chapters 17 through 20 consider the neurobiology of neuropsychiatric and neurodegenerative disorders and the drugs used to treat these disorders. Among the neuropsychiatric disorders, special emphasis is placed on affective disorders such as major depression and bipolar disorder, various anxiety disorders, and schizophrenia. Bulleted interim summaries highlight the key points made in each part of the chapter. New to this edition, study questions are provided at the end of each chapter to assist students in reviewing the most important material. Finally, a dedicated website for the book ([oup-arc.com/access/meyer-3e](http://oup-arc.com/access/meyer-3e)) is available that offers Web Boxes (advanced topics for interested readers), study resources such as flashcards, web links, and animations that visually illustrate key neurophysiological and neurochemical processes important for psychopharmacology.

It has been our privilege in the first two editions of *Psychopharmacology: Drugs, the Brain, and Behavior* to introduce so many students to the study of drugs and behavior. With this new and updated edition, we hope to continue this tradition and perhaps inspire some of you to continue your studies in graduate school and join the thousands of researchers worldwide who are working to better understand and ultimately defeat illnesses like addiction, depression, schizophrenia, and Alzheimer's disease.

## Acknowledgments

This book is the culmination of the efforts of many dedicated people who contributed their ideas and hard work to the project. We'd like to thank and acknowledge the outstanding editorial team at Sinauer Associates: Sydney Carroll, Martha Lorantos, and Danna Lockwood, thank you all for your suggestions for improving the Third Edition, your help and guidance throughout the process of writing and revising, and not least for your patience (textbook writing is a slow process when one is simultaneously teaching, conducting research, and meeting administrative responsibilities). You were unwavering in your vision to produce the best possible psychopharmacology textbook. Mark Siddall did a superb job of seeking out just the right photographs for the book. We are indebted to other key staff members of Sinauer Associates who worked on this project, including Chris Small, Ann Chiara, and Joan Gemme. And we must acknowledge Dragonfly Media Group for the beautiful job rendering the illustrations.

The following reviewers contributed many excellent suggestions for improving the book:

Joel Alexander, Western Oregon University  
 Sage Andrew, University of Missouri  
 Susan Barron, University of Kentucky  
 Ethan Block, University of Pittsburgh  
 Kirstein Cheryl, University of South Florida  
 Matt Clasen, American University  
 Patricia DiCiano, The Centre for Addiction and  
 Mental Health and Seneca College

Henry Gorman, Austin College  
 Bill Griesar, Portland State University  
 Joshua Gulley, University of Illinois at Urbana-  
 Champaign  
 Matt Holahan, Carleton University  
 Phillip Holmes, University of Georgia  
 Michael Kane, University of Pennsylvania  
 Thomas Lanthorn, Sam Houston State University  
 Lauren Liets, University of California, Davis  
 Ilyssa Loiacono, Queens College  
 Margaret Martinetti, The College of New Jersey  
 Janice McMurray, University of Nevada, Las Vegas  
 M. Foster, Olive Arizona State University  
 Robert Patrick, Brown University  
 Anna Rissanen, Memorial University, Newfoundland  
 Margaret Ruddy, The College of New Jersey  
 Jeffrey Rudski, Muhlenberg College  
 Lawrence Ryan, Oregon State University  
 Fred Shaffer, Truman State University  
 Evan Zucker, Loyola University

Most of all, we are indebted to our spouses, Melinda Novak and Ray Rosati, who supported and encouraged us and who willingly sacrificed so much of our time together during this lengthy project. Linda gives special thanks to her husband Ray for providing extensive editorial advice during the final production period.

# Media and Supplements to accompany *Psychopharmacology*, Third Edition

## FOR THE STUDENT

### Companion Website

(oup-arc.com/access/meyer-3e)

The *Psychopharmacology*, Third Edition companion website provides students with a variety of resources to help them learn and review the material presented in the textbook and to expand the coverage of the textbook. The site is available to students free of charge and includes the following resources:

- *Chapter Outlines & Summaries* provide detailed reviews of each chapter.
- *Animations* give students detailed, narrated depictions of some of the complex processes described in the textbook.
- *Web Boxes* include coverage of novel and cutting-edge topics useful for special discussion.
- *Web Links* list suggested websites and other online resources related to each chapter.
- *Suggested Readings* provide additional references and readings for each chapter.
- *Flashcards* help students master the hundreds of new terms introduced in the textbook.
- An online *Glossary* provides definitions for all textbook bolded terms.

## Value Option

### eBook

(ISBN 978-1-60535-728-7)

*Psychopharmacology*, Third Edition is available as an eBook in several formats, including RedShelf, VitalSource, and Chegg. All major mobile devices are supported.

## FOR THE INSTRUCTOR

### Ancillary Resource Center

(oup-arc.com)

- *Textbook Figures and Tables (JPEG)*: All of the figures and tables from the textbook, formatted for optimal legibility when projected. Complex images are provided in both whole and split versions.
- *PowerPoint Presentations*: For each chapter of the textbook, two PowerPoint presentations are provided:
  - *Figures & Tables*: All of the figures and tables from the chapter, with figure numbers and titles on each slide and complete captions in the Notes field.
  - *Lecture*: A complete lecture outline with selected figures and tables.
- *Test Bank*: A complete set of multiple-choice and short-answer questions for each chapter of the textbook. Questions address the full range of material covered in each chapter, including both factual and conceptual questions, and all are keyed to specific textbook sections. Test Banks are available in Microsoft Word, Diploma, and LMS formats.

To learn more about any of these resources, or to get access, please contact your local OUP representative.

# Psychopharmacology

Drugs, the Brain, and Behavior

THIRD EDITION

# CHAPTER 1



Maggot therapy can be used to clean wounds and prevent infection.  
(PA Images/Alamy Stock Photo.)

# Principles of Pharmacology

**WILLIAM S. BAER (1872–1931) WAS AN ORTHOPEDIC SURGEON** at Johns Hopkins University, where he established the orthopedic department and led it for most of his life, training many of the outstanding orthopedists of the day. During World War I Baer observed that soldiers who had severe and deep flesh wounds did not have the fever associated with infection and showed little of the expected necrotic (dead) tissue damage if there was a significant presence of maggots (fly larvae) in the wounds. Although it had been believed that early peoples (Australian aborigines and Mayan Indian tribes) and others throughout history had used maggots to clean wounds, it was Baer who once again recognized their importance, especially in tense battlefield conditions where infection was especially hard to treat. Apparently the maggots ingested the dying tissue but left healthy tissue intact. Baer, upon doing further “pharmacological” experiments, showed that his hospitalized patients with severe and chronic bone infections showed remarkable recovery after being treated with maggots—the inflamed and dying tissue was ingested, leaving wounds clean and healthy, and new tissue formed. As long as the maggots were sterilized, secondary infections were avoided. After his research, “maggot therapy” became popular and was used throughout the 1930s and 1940s until penicillin was established as an easier treatment for infection. However, it has been suggested that in modern times, maggot therapy will be reintroduced to treat those wounds infected with antibiotic-resistant bacteria. Presently in the European Union, Japan, and Canada, maggots are considered “medicinal drugs,” and in 2005 the U.S. Food and Drug Administration approved the use of maggots as a medical “device.”

What actually causes the amazing healing process is not entirely clear, but pharmacologists are beginning to understand that maggot secretions suppress the immune system and reduce inflammation, and they may also enhance cell growth and increase oxygen concentration in the wound. This is certainly not the first time pharmacology has returned to earlier forms of therapeutics, but the science now can isolate and identify those components that lead to healing. ■



## Pharmacology: The Science of Drug Action

**Pharmacology** is the scientific study of the actions of drugs and their effects on a living organism. Until the beginning of the last century, pharmacologists studied drugs that were almost all naturally occurring substances. The importance of plants in the lives of ancient humans is well documented. Writings from as early as 1500 BCE describe plant-based medicines used in Egypt and in India. The Ebers Papyrus describes the preparation and use of more than 700 remedies for ailments as varied as crocodile bites, baldness, constipation, headache, and heart disease. Of course, many of these treatments included elements of magic and incantation, but there are also references to some modern drugs such as castor oil and opium. The Chinese also have a very long and extensive tradition in the use of herbal remedies that continues today. World Health Organization estimates suggest that in modern times, as many as 80% of the people in developing countries are totally dependent on herbs or plant-derived medicinals. And in 1999, in the United States, modern herbal medicines and drugs based on natural products represented half of the top 20 drugs on the market (Hollinger, 2008). Many Americans are enamored with herbal medications despite limited clinical support for their effectiveness, because they believe these treatments are more “natural.” Nevertheless, serious dangers have been associated with some of them. **Web Box 1.1** discusses the benefits and dangers of herbal remedies.

When placed in historical context, it can be seen that drug development in the United States is in its infancy. The rapid introduction of many new drugs by the pharmaceutical industry has forced the development of several specialized areas of pharmacology. Two of these areas are of particular interest to us. **Neuropharmacology** is concerned with drug-induced changes in the functioning of cells in the nervous system, and **psychopharmacology** emphasizes drug-induced changes in mood, thinking, and behavior. In combination, the goal of **neuropsychopharmacology** is to identify chemical substances that act on the nervous system to alter behavior that is disturbed because of injury, disease, or environmental factors. Additionally, neuropsychopharmacologists are interested in using chemical agents as probes to gain an understanding of the neurobiology of behavior.

When we speak of **drug action**, we are referring to the specific molecular changes produced by a drug when it binds to a particular target site or receptor. These molecular changes lead to more widespread alterations in physiological or psychological functions, which we consider **drug effects**. The site of drug action may be very different from the site of drug effect. For example, atropine is a drug used in ophthalmology

to dilate the pupil of the eye before eye examinations. Atropine has a site of action (the eye muscles of the iris) that is close to the site of its ultimate effect (widening the pupil), so it is administered directly to the eye. In comparison, morphine applied to the eye itself has no effect. Yet when it is taken internally, the drug’s action on the brain leads to “pinpoint” pupils. Clearly, for morphine, the site of effect is far distant from the site of its initial action.

Keep in mind that because drugs act at a variety of target sites, they always have multiple effects. Some may be **therapeutic effects**, meaning that the drug–receptor interaction produces desired physical or behavioral changes. All other effects produced are referred to as **side effects**, and they vary in severity from mildly annoying to distressing and dangerous. For example, amphetamine-like drugs produce alertness and insomnia, increased heart rate, and decreased appetite. Drugs in this class reduce the occurrence of spontaneous sleep episodes characteristic of the disorder called *narcolepsy*, but they produce anorexia (loss of appetite) as the primary side effect. In contrast, the same drug may be used as a prescription diet control in weight-reduction programs. In such cases, insomnia and hyperactivity are frequently disturbing side effects. Thus therapeutic and side effects can change, depending on the desired outcome.

It is important to keep in mind that there are no “good” or “bad” drugs, because all drugs are just chemicals. It is the way a drug is procured and used that determines its character. Society tends to think of “good” drugs as those purchased at a pharmacy and taken at the appropriate dosage for a particular medicinal purpose, and “bad” drugs as those acquired in an illicit fashion and taken recreationally to achieve a desired psychological state. Even with this categorization, the differences are blurred because many people consider alcohol to be “bad” even though it is purchased legally. Morphine and cocaine have legitimate medicinal uses, making them “good drugs” under some conditions, although they can, when misused, lead to dangerous consequences and addiction, making the same drugs “bad.” Finally, many “good” prescription drugs are acquired illicitly or are misused by increasing the dose, prolonging use, or sharing the drug with other individuals, leading to “bad” outcomes. As you will read in later chapters, the ideas of Americans about appropriate drug use have changed dramatically over time (see the sections on the history of the use of narcotics in Chapter 11 and cocaine in Chapter 12).

Many of the drug effects we have described so far have been **specific drug effects**, defined as those based on the physical and biochemical interactions of a drug with a target site in living tissue. In contrast, **nonspecific drug effects** are those that are based not on the chemical activity of a drug–receptor interaction,

but on certain unique characteristics of the individual. It is clear that an individual's background (e.g., drug-taking experience), present mood, expectations of drug effect, perceptions of the drug-taking situation, attitude toward the person administering the drug, and other factors influence the outcome of drug use. Nonspecific drug effects help to explain why the same individual self-administering the same amount of ethyl alcohol may experience a sense of being lighthearted and gregarious on one occasion, and depressed and melancholy on another. The basis for such a phenomenon may well be the varied neurochemical states existing within the individual at different times, over which specific drug effects are superimposed.

### Placebo effect

Common examples of nonspecific effects are the multiple outcomes that result from taking a **placebo**. Many of you automatically think of a placebo as a "fake" pill. A placebo *is* in fact a pharmacologically inert compound administered to an individual; however, in many instances it has not only therapeutic effects, but side effects as well. Just as many of the symptoms of illness may have psychogenic or emotional origins, belief in a drug may produce real physiological effects despite the lack of chemical activity. These effects are not limited to the individual's subjective evaluation of relief, but include measurable physiological changes such as altered gastric acid secretion, blood vessel dilation, hormonal changes, and so forth.

In a classic study, two groups of patients with ulcers were given a placebo. In the first group, the medication was provided by a physician, who assured the patients that the drug would provide relief. The second group also received the placebo, but it was administered by a nurse, who described it as experimental in nature. In group 1, 70% of the patients found significant relief, but in group 2, only 25% were helped by the "drug" (Levine, 1973). Based on these results, it is clear that a sugar pill is not a drug that can heal ulcers, but rather its effectiveness depends on the ritual of the therapeutic treatment that can have both neurobiological and behavioral effects that influence the outcome. It is a perfect example of mind–body interaction, and there has been increasing interest in understanding the mechanism responsible for the placebo effect as a means to enhance the therapeutic effectiveness of drug treatments. Although some consider deliberate prescription of placebos to patients unethical because of the deception involved, other physicians and ethicists have identified appropriate uses for placebos that represent an inexpensive treatment that avoids interactions with other medications.


Placebo effects may in part be explained by Pavlovian conditioning in which symptom improvement in the past has been associated with particular

characteristics of a medication, for example, its taste, color, shape, and size; a particular recommending clinician, with her white coat, reassuring tone of voice, or attitude; or aspects of the medical facility. Since a placebo effect has been demonstrated many times in animal models, cues in the environment are apparently sufficient, and verbal reassurances are not necessary. In fact, patients have been shown to benefit even if they are told that the medication is a placebo, so deception is apparently not a necessity; however, verbal suggestion interacts with conditioning (see Colagiuri et al., 2015). There have been suggestions that patients might be trained to respond to a placebo by alternating days of placebo treatment with days of active drug treatment. That would allow the reduction of the use of the active agent, potentially minimizing side effects and reducing the cost of treatment.

A second possible explanation for the placebo effect is that of conscious, explicit expectation of outcomes. For example, those individuals who anticipate relief, that is, individuals with an optimistic outlook, may show an enhanced placebo response. Of great interest are the placebo-induced neurobiological effects within the brain. Research has shown that when placebos effectively reduce pain, those individuals who are responders have significantly higher levels of natural pain-relieving opioid neuropeptides in their cerebrospinal fluid than those individuals who do not show a response to the placebo. Further, the subjects who anticipate pain relief show reduced neural activity in pain-related brain regions (see Benedetti et al., 2011).

There is every reason to believe that Pavlovian conditioning and conscious expectation both contribute to the placebo effect, but other factors may also have a part (see Carlino et al., 2016; Murray and Stoessl, 2013). Placebo effects may involve social learning. That is, observing another individual anticipating a positive outcome can be a more powerful inducer of the placebo effect than direct conditioning or verbal suggestions. Others have found that anticipating a successful outcome reduces anxiety and activates reward networks in the brain. Finally, a number of genetic variants have been found that influence the placebo effect. Understanding more about which genes identify patients who will respond to placebo could allow treatment to be adjusted to maximize outcome (Colagiuri et al., 2015). This is one step toward personalized medicine (see the last section of this chapter). A model of these psychosocial–psychobiological factors is shown in **FIGURE 1.1**.

In contrast to placebos, negative expectations may increase the level of anxiety experienced, which may also influence outcome of treatment. Expecting treatment failure when an inert substance is given along with verbal suggestions of negative outcome, such as increased pain or another aversive event, would increase anxiety as well as causing an accompanying change in



**FIGURE 1.1 Placebo effects** A model of psychosocial–psychobiological factors that influence clinical improvement following placebo administration. (After Benedetti et al., 2011.)

neural mechanisms, including increases in stress hormones. This is the **nocebo** effect, and both the nocebo-induced increase in pain reported and the hormonal stress response can be reduced by treatment with an anti-anxiety drug, demonstrating that expectation-induced

anxiety plays a part in the nocebo effect. Nocebos are important to study because warnings about potential side effects can lead to greater side effect occurrence. Unfortunately, because drug companies are required by law to provide a comprehensive listing of all possible side effects, many individuals have negative expectations, leading to increased side effects.

In pharmacology, the placebo is essential in the design of experiments conducted to evaluate the effectiveness of new medications, because it eliminates the influence of expectation on the part of the experiment’s participants. The control group is identical to the experimental group in all ways and is unaware of the substitution of an inactive substance (e.g., sugar pill, saline injection) for the test medication. Comparison of the two groups provides information on the effectiveness of the drug beyond the expectations of the participants. Of course, drugs with strong subjective effects or prominent side effects make placebo testing more challenging because the experimental group will be aware of the effects while those experiencing no effects will conclude they are the control group. To avoid that problem, some researchers may use an “active” placebo, which is a drug (unrelated to the drug being tested) that produces some side effects that suggest to the control participants that they are getting the active agent. In other cases clinical researchers may feel that it is unethical to leave the placebo group untreated if there is an effective agent available. In that case the control group will be given the older drug, and

## BOX 1.1 Pharmacology in Action

### Naming Drugs

Drug names can be a confusing issue for many people because drugs that are sold commercially, by prescription or over the counter, usually have four or more different kinds of names. All drugs have a chemical name that is a complete chemical description suitable for synthesizing by an organic chemist. Chemical names are rather clumsy and are rarely used except in a laboratory setting. In contrast, generic names (also called nonproprietary names) are official names of drugs that are listed in the United States Pharmacopeia. The generic name is a much shorter form of the chemical name but is still unique to that drug. For example, one popular anti-anxiety drug has the chemical name 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one and the generic name diazepam. The brand name, or trade name, of that drug (Valium) specifies a particular manufacturer and a formulation. A brand name

is trademarked and copyrighted by an individual company, which means that the company has an exclusive right to advertise and sell that drug.

Slang or street names of commonly abused drugs are another way to identify a particular chemical. Unfortunately, these names change over time and vary with geographic location and particular groups of people. In addition, there is no way to know the chemical characteristics of the substance in question. Some terms are used in popular films or television and become more generally familiar, such as “crack” or “ice,” but most disappear as quickly as they appear. The National Institute on Drug Abuse (NIDA) has compiled a list of more than 150 street names for marijuana and more than 75 for cocaine, including coke, big C, nose candy, snow, mighty white, Foofoo dust, Peruvian lady, dream, doing the line, and many others.

effectiveness of the new drug will be compared with it rather than with a placebo.

The large contribution of nonspecific factors and the high and variable incidence of placebo responders make the **double-blind experiment** highly desirable. In these experiments, neither the patient nor the observer knows what treatment the participant has received. Such precautions ensure that the results of any given treatment will not be colored by overt or covert prejudices on the part of the participant or the observer. If you would like to read more about the use of placebos in both clinical research and therapeutics and the associated ethical dilemmas, refer to the articles by Brown (1998) and Louhiala (2009).


Throughout this chapter, we present examples that include both therapeutic and recreational drugs that affect mood and behavior. Since there are usually several names for the same substance, it may be helpful for you to understand how drugs are named (**BOX 1.1**).

## Pharmacokinetic Factors Determining Drug Action

Although it is safe to assume that the chemical structure of a drug determines its action, it quickly becomes clear that additional factors are also powerful

contributors. The dose of the drug administered is clearly important, but more important is the amount of drug in the blood that is free to bind at specific target sites (**bioavailability**) to elicit drug action. The following sections of this chapter describe in detail the dynamic factors that contribute to bioavailability. Collectively, these factors constitute the **pharmacokinetic** component of drug action; they are listed below and illustrated in **FIGURE 1.2**.

1. *Routes of administration.* How and where a drug is administered determines how quickly and how completely the drug is absorbed into the blood.
2. *Absorption and distribution.* Because a drug rarely acts where it initially contacts the body, it must pass through a variety of cell membranes and enter the blood plasma, which transports the drug to virtually all of the cells in the body.
3. *Binding.* Once in the blood plasma, some drug molecules move to tissues to bind to active target sites (receptors). While in the blood, a drug may also bind (**depot binding**) to plasma proteins or may be stored temporarily in bone or fat, where it is inactive.
4. *Inactivation.* Drug inactivation, or **biotransformation**, occurs primarily as a result of metabolic



**FIGURE 1.2** Pharmacokinetic factors that determine bioavailability of drugs From the site of administration (1), the drug moves through cell membranes to be absorbed into the blood (2), where it circulates to all cells in the body. Some of the drug molecules may bind to inactive

sites such as plasma proteins or storage depots (3), and others may bind to receptors in target tissue. Blood-borne drug molecules also enter the liver (4), where they may be transformed into metabolites and travel to the kidneys and other discharge sites for ultimate excretion (5) from the body.

processes in the liver as well as other organs and tissues. The amount of drug in the body at any one time is dependent on the dynamic balance between absorption and inactivation. Therefore, inactivation influences both the intensity and the duration of drug effects.

5. *Excretion.* The liver metabolites are eliminated from the body with the urine or feces. Some drugs are excreted in an unaltered form by the kidneys.

Although these topics are discussed sequentially in the following pages, keep in mind that in the living organism, these factors are at work simultaneously. In addition to bioavailability, the drug effect experienced will also depend on how rapidly the drug reaches its target, the frequency and history of prior drug use (see the discussion on tolerance later in the chapter), and nonspecific factors that are characteristics of individuals and their environments.

### Methods of drug administration influence the onset of drug action

The route of administration of a drug determines how much drug reaches its site of action and how quickly the drug effect occurs. There are two major categories of administration methods. **Enteral** methods of administration use the gastrointestinal (GI) tract (*enteron* is the Greek word for “gut”); agents administered by these methods are generally slow in onset and produce highly variable blood levels of drug. The most common enteral method of administration is oral, but rectal administration with the use of suppositories is another enteral route. All other routes of administration are **parenteral** and include those that do not use the alimentary canal, such as injection, pulmonary, and topical administration.


**Oral administration (PO)** is the most popular route for taking drugs, because it is safe, self-administered, and economical, and it avoids the complications and discomfort of injection methods. Drugs that are taken orally come in the form of capsules, pills, tablets, or liquid, but to be effective, the drug must dissolve in stomach fluids and pass through the stomach wall to reach blood capillaries. In addition, the drug must be resistant to destruction by stomach acid and stomach enzymes that are important for normal digestion. Insulin is one drug that can be destroyed by digestive processes, and for this reason it currently cannot be administered orally. However, several pharmaceutical companies have been actively testing various forms of insulin, believing an oral drug would make insulin therapy for diabetes less complicated and unpleasant and lead to better compliance with the treatment regimen. Although there is no oral insulin, there are some oral medications available that may be effective for some diabetic patients because they inhibit the digestion of

starches or increase the amount of glucose excreted in the urine.

Movement of the drug from the site of administration to the blood circulation is called **absorption**. Although some drugs are absorbed from the stomach, most drugs are not fully absorbed until they reach the small intestine. Many factors influence how quickly the stomach empties its contents into the small intestine and hence determine the ultimate rate of absorption. For example, food in the stomach, particularly if it is fatty, slows the movement of the drug into the intestine, thereby delaying absorption into the blood. The amount of food consumed, the level of physical activity of the individual, and many other factors make it difficult to predict how quickly the drug will reach the intestine. In addition, many drugs undergo extensive first-pass metabolism. **First-pass metabolism** is an evolutionarily beneficial function because potentially harmful chemicals and toxins that are ingested pass via the portal vein to the liver, where they are chemically altered by a variety of enzymes before passing to the heart for circulation throughout the body (**FIGURE 1.3**). Unfortunately, some therapeutic drugs taken orally may undergo extensive metabolism (more than 90%), reducing their bioavailability. Drugs that show extensive first-pass effects must be administered at higher doses or in an alternative manner, such as by injection. Because of these many factors, oral administration produces drug plasma levels that are more irregular and unpredictable and rise more slowly than those produced by other methods of administration.

**Rectal administration** requires the placement of a drug-filled suppository in the rectum, where the suppository coating gradually melts or dissolves, releasing the drug, which will be absorbed into the blood. Depending on the placement of the suppository, the drug may avoid some first-pass metabolism. Drug absorbed from the lower rectum into the hemorrhoidal vein bypasses the liver. However, deeper placement means that the drug is absorbed by veins that drain into the portal vein, going to the liver before the general circulation. Bioavailability of drugs administered in this way is difficult to predict, because absorption is irregular. Although rectal administration is not used as commonly as oral administration, it is an effective route in infants and in individuals who are vomiting, unconscious, or unable to take medication orally.

**Intravenous (IV)** injection is the most rapid and accurate method of drug administration in that a precise quantity of the agent is placed directly into the blood and passage through cell membranes such as the stomach wall is eliminated (see Figure 1.3). However, the quick onset of drug effect with IV injection is also a potential hazard. An overdose or a dangerous allergic reaction to the drug leaves little time for corrective measures, and the drug cannot be removed from the



**FIGURE 1.3 Routes of drug administration** First-pass effect. Drugs administered orally are absorbed into the blood and must pass through the liver before reaching the general circulation. Some drug molecules may be destroyed in the liver before they can reach target tissues. The arrows indicate the direction of blood flow in the arteries (red) and veins (blue). (Top inset) Pulmonary absorption

through capillaries in the alveoli. Rapid absorption occurs after inhalation because the large surface area of the lungs and the rich capillary networks provide efficient exchange of gases to and from the blood. (Bottom inset) Methods of administration by injection. The speed of absorption of drug molecules from administration sites depends on the amount of blood circulating to that area.

body as it can be removed from the stomach by stomach pumping.

For drug abusers, IV administration provides a more dramatic subjective drug experience than self-administration in other ways, because the drug reaches the brain almost instantly. Drug users report that intravenous injection of a cocaine solution usually produces an intense “rush” or “flash” of pure pleasure that lasts for approximately 10 minutes. This experience rarely occurs when cocaine is taken orally or is taken into the nostrils (snorting; see the discussion on topical administration). However, intravenous use of street drugs poses several special hazards. First, drugs that are impure or of unknown quality provide uncertain doses, and toxic reactions are common. Second, lack of sterile injection equipment and aseptic technique can lead to infections such as hepatitis, human immunodeficiency

virus (HIV), and endocarditis (inflammation of the lining of the heart). Fortunately, many cities have implemented free needle programs, which significantly reduce the probability of cross infection. Third, many drug abusers attempt to dissolve drugs that have insoluble filler materials, which, when injected, may become trapped in the small blood vessels in the lungs, leading to reduced respiratory capacity or death.

An alternative to the IV procedure is **intramuscular (IM)** injection, which provides the advantage of slower, more even absorption over a period of time. Drugs administered by this method are usually absorbed within 10 to 30 minutes. Absorption can be slowed down by combining the drug with a second drug that constricts blood vessels, because the rate of drug absorption is dependent on the rate of blood flow to the muscle (see Figure 1.3). To provide slower, sustained action, the